Together these data indicate that despite a trend for increased ductular proliferation, treatment with the GLP-2 analogue teduglutide reduced secretion of proinflammatory markers, such as osteopontin and Vcam-1, from cholangiocytes in the Mdr2-/- mouse model of sclerosing cholangitis. This evidence concerns the gene SPP1 and sclerosing cholangitis.